Valganciclovir
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Valganciclovir
Valganciclovir: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Valganciclovir, so there is currently no new predicted indication. The recorded uses for this drug are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 0 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10277X | Valcyte | Powder for oral solution 50 mg (as hydro | Valid |
Safety Considerations
- Drug Interactions: The data compiled for this report list 100 potential interactions. The moderate-level ones are amphotericin B (including lipid complex, cholesteryl sulfate and liposomal formulations) and trospium. Other interactions are of unknown severity, including pantoprazole, omeprazole, lansoprazole, metformin, morphine, simvastatin, prednisone, hydrocortisone, vancomycin and calcitriol.
Warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.